Cullinan Therapeutics, Inc. (NASDAQ: CGEM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $33.00 price target on the stock.
Cullinan Therapeutics Receives Approval from European Medicines Agency to Initiate Phase 1 Trial of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Rheumatoid Arthritis
Cullinan Therapeutics, Inc. (NASDAQ: CGEM) had its "overweight" rating re-affirmed by analysts at Morgan Stanley. They now have a $35.00 price target on the stock, down previously from $38.00.
Cullinan Therapeutics, Inc. (NASDAQ: CGEM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $33.00 price target on the stock.
Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results